Frank Osterroth

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells <i>In vitro</i> and <i>In vivo</i>

Hiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti et al. · Clinical Cancer Research · 2009 · 204 citations · Full text

Medicine, Oncology, Pharmacology +14

Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells

Frank Osterroth, Annette I. Garbe, Paul Fisch et al. · Blood · 2000 · 72 citations

Life Sciences, Immunology, Oncology +17

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

Leonard T. Heffner, Sundar Jagannath, Todd M. Zimmerman et al. · Blood · 2012 · 60 citations

Pharmacy, Oncology, Pharmacology +12

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, Asher Chanan‐Khan, Leonard T. Heffner et al. · Blood · 2011 · 44 citations

Medicine, Hematology, Oncology +14

A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway

Bianca Helling, Martin König, Benjamin Dälken et al. · Immunology and Cell Biology · 2014 · 38 citations · Full text

Life Sciences, Immunology, Molecular Biology +17